Heath State Utility Values for Cost-Effectiveness Models

PharmacoEconomics - Tập 35 - Trang 1-3 - 2017
Jonathan Karnon1
1School of Public Health, University of Adelaide, Adelaide, Australia

Tài liệu tham khảo

Karnon J, Brennan A, Akehurst R. Decision modeling to inform decision making: seeing the wood for the trees. Med Decis Mak. 2010;30(3):E20–2.

Ara R, Peasgood T, Brazier J, Mukuria C, Chevrou-Severac H, Rowen D, et al. Sourcing and using appropriate health state utility values in economic models in health care. Pharmacoeconomics. 2017. doi:10.1007/s40273-017-0543-z.

Rowen D, Azzabi Zouraq I, Chevrou-Severac H, van Hout B. International regulations and recommendations for utility data for health technology assessment. Pharmacoeconomics. 2017. doi:10.1007/s40273-017-0544-y.

Brazier J, Ara R, Donna Rowen D, Chevrou-Severac H. A review of generic preference-based measures for use in cost-effectiveness models. Pharmacoeconomics. 2017. doi:10.1007/s40273-017-0545-x.

Ara R, Brazier J, Azzabi Zouraq I. The use of health state utility values in decision models. Pharmacoeconomics. 2017. doi:10.1007/s40273-017-0550-0.

Ara R, Brazier J. Estimating HSUVs for comorbidities. Pharmacoeconomics. 2017. doi:10.1007/s40273-017-0551-z.

Ara R, Brazier J, Peasgood T, Suzy Paisley S. The identification, review and synthesis of HSUVs from the literature. Pharmacoeconomics. 2017. doi:10.1007/s40273-017-0547-8.

Peasgood T, Brazier J. Is meta-analysis for utility values appropriate given the potential impact different elicitation methods have on values? Pharmacoeconomics. 2015;33(11):1101–5.

The Australian Commission on Safety and Quality in Health Care. Economic evaluation of clinical quality registries: Final report. Sydney: ACSQHC; 2016.

Thông tin
Thông tin xuất bản

PharmacoEconomics

Tập 35

1-3

Thông tin tác giả